Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.
Firas El Chaer, MD
Advertisement
Articles by Firas El Chaer, MD
Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.
Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.
Advertisement
Latest Updated Articles
Dr. El Chaer on the Potential for Combination Strategies With Ruxolitinib in MPNsPublished: November 25th 2020 | Updated:
Dr. El Chaer on the Role of Next-Generation Sequencing in MPNsPublished: December 4th 2020 | Updated:
Dr. El Chaer on the Limitations of JAK Inhibitors in MyelofibrosisPublished: November 17th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5